Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100


The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.

Freitas DMO, Andriole GL, Castro-Santamaria R, Freedland SJ, Moreira DM.

Scand J Urol. 2019 Feb 14:1-5. doi: 10.1080/21681805.2018.1551244. [Epub ahead of print]


Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2018 Dec 28. pii: S1078-1439(18)30496-4. doi: 10.1016/j.urolonc.2018.12.004. [Epub ahead of print]


Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.


Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.


Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2018 Oct 22. doi: 10.1111/bju.14594. [Epub ahead of print]


Nocturia and associated mortality: observational data from the REDUCE trial.

Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):77-83. doi: 10.1038/s41391-018-0090-5. Epub 2018 Sep 13.


Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ.

J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6.


Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial.

Allott EH, Markt SC, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Mucci LA, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):783-789. doi: 10.1158/1055-9965.EPI-18-0076. Epub 2018 Apr 18.


Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ.

Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.


Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.

Xiao J, Howard L, Wan J, Wiggins E, Vidal A, Cohen P, Freedland SJ.

Oncotarget. 2017 Aug 10;8(55):94900-94909. doi: 10.18632/oncotarget.20134. eCollection 2017 Nov 7.


Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urology. 2017 Dec;110:76-83. doi: 10.1016/j.urology.2017.08.024. Epub 2017 Aug 25.


Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy.

Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ.

Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.


Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.


Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.

Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ; Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group.

Cancer. 2017 Nov 1;123(21):4199-4206. doi: 10.1002/cncr.30834. Epub 2017 Jun 27.


Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.

Vidal AC, Freedland SJ.

Eur Urol. 2017 Jul;72(1):78-83. doi: 10.1016/j.eururo.2016.10.011. Epub 2016 Oct 19. Review.


Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR.

J Urol. 2016 Nov;196(5):1408-1414. doi: 10.1016/j.juro.2016.06.086. Epub 2016 Jun 25.


Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ.

Clin Genitourin Cancer. 2017 Feb;15(1):60-66.e2. doi: 10.1016/j.clgc.2016.08.018. Epub 2016 Aug 31.


The association between sexual function and prostate cancer risk in US veterans.

Zapata DF, Howard LE, Frank J, Simon RM, Hoyo C, Grant DJ, Freedland SJ, Vidal AC.

Asian J Androl. 2017 Mar-Apr;19(2):191-195. doi: 10.4103/1008-682X.184869.


Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2016 Dec 15;122(24):3848-3855. doi: 10.1002/cncr.30221. Epub 2016 Aug 9.


Racial differences in prostate inflammation: results from the REDUCE study.

Vidal AC, Chen Z, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Taioli E, Fowke JH, Knudsen B, Drake CG, Nickel JC, Freedland SJ.

Oncotarget. 2016 Jul 18;8(42):71393-71399. doi: 10.18632/oncotarget.10690. eCollection 2017 Sep 22.

Supplemental Content

Loading ...
Support Center